EDX Medical Group Plc (EDX.AQ)

7.50 +0.40 (+5.63%) At close: 10:53AM BST

EDX Medical Group Plc

210-211 Milton Road
Cambridge CB4 0WA
United Kingdom

https://www.edxmedical.co.uk

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael John Hudson	CEO & Director	N/A	N/A	1958
Sir Christopher Thomas Evans ARCS, B.Sc., DSc, FIB, FMEDSCI, FREng, FRSA, FRSC	Founder, Chief Scientific Officer & Director	N/A	N/A	1957
Dr. Liam Dower	Head of Quality, Regulatory Affairs & Compliance	N/A	N/A	N/A
Dr. Keti Zeka	Head of R&D and Director of Laboratories	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

EDX Medical Group Plc engages in developing a range of diagnostics testing solutions in the United Kingdom. It engages in the development of tests for diabetes, obesity, inflammatory disorders, and kidney and liver disorders. The company was formerly known as TECC Capital PLC and changed its name to EDX Medical Group Plc in November 2022. EDX Medical Group Plc was incorporated in 2021 and is based in Cambridge, the United Kingdom.

Corporate governance

EDX Medical Group Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.